Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
ACAD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.15 - $20.68
Previous CloseN/A
Volume443.16K
Average Volume (3M)1.83M
Market Cap
$2.80B
Enterprise Value$2.04B
Total Cash (Recent Filing)$319.59M
Total Debt (Recent Filing)$51.99M
Price to Earnings (P/E)12.7
Beta1.37
Next Earnings
May 13, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.36
Shares Outstanding166,788,510
10 Day Avg. Volume1,795,154
30 Day Avg. Volume1,825,899
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.92
Price to Cash Flow (P/CF)17.30
P/FCF Ratio17.30
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.33
Enterprise Value/Ebitda20.90
Forecast
1Y Price Target
$26.14Price Target Upside52.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
---
Bulls Say, Bears Say
Bulls Say
Patent ProtectionPatent protection for Nuplazid is anticipated to extend to 2030, resulting in peak sales of ~$800M and ~$2.4B in residuals post-expiry.
Pipeline DevelopmentThe pipeline is maturing with data readouts expected in 2026, suggesting future potential for the company.
Sales GrowthACAD is expected to deliver +11% net product sales growth in 2025 to ~$1.1B.
Bears Say
Daybue SalesCaution on consensus Daybue sales forecast and the paucity of near-term catalysts other than Nuplazid district court decision.
Sales Guidance2025 Daybue sales guidance was lower than expected.
Spending Guidance2025 SG&A/R&D spending guidance was also above expectations.
---
Ownership Overview
24.05% Insiders
15.15% Mutual Funds
0.31% Other Institutional Investors
37.31% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACAD FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $14.15 and its highest was $20.68 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is $2.80B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 47 days.
How were ACADIA Pharmaceuticals’s earnings last quarter?
ACADIA Pharmaceuticals released its earnings results on Feb 26, 2025. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.216 by $0.644.
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is -0.02.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 166,788,510 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
ACADIA Pharmaceuticals reported an EPS of $0.86 in its last earnings report, beating expectations of $0.216. Following the earnings report the stock price went up 1.789%.
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in ACAD
---
ACADIA Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.14 (52.78% Upside)
$26.14 (52.78% Upside)
Blogger Sentiment
Bullish
ACAD Sentiment 66%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 514.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $89.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-4.01%
12-Months-Change
Fundamentals
Return on Equity
38.89%
Trailing 12-Months
Asset Growth
58.59%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
---
ACAD Company Deck
---
ACAD Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial results, pipeline expansion, and global growth plans, but also acknowledged challenges in revenue guidance due to pricing and regulatory uncertainties. Despite these hurdles, the company remains optimistic about its future growth and strategic initiatives.Read More>---
ACAD Stock 12 Month Forecast
Average Price Target
$26.14
▲(52.78% Upside)
Technical Analysis
Neurocrine
―
Prothena
―
Intra-Cellular Therapies
―
SAGE Therapeutics
―
Axsome Therapeutics
―
Best Analysts Covering ACAD
1 Year
1 Year Success Rate
15/27 ratings generated profit
1 Year Average Return
+6.65%
reiterated a buy rating 29 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +6.65% per trade.
---